Results 41 to 50 of about 5,288 (183)

Ibrutinib‐induced severe liver injury

Clinical Case Reports, 2017
Key Clinical Message Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known.
Amara G. Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram   +7 more
doaj   +1 more source

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Journal of Hematology & Oncology, 2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic ...
Jingjing Wu, Mingzhi Zhang, Delong Liu
doaj   +1 more source

Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis

Advanced Science, EarlyView.
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen, Jingke Li, Yangyang Liu, Li Li, Xin Deng, Yilin Sheng, Xianyu Zhu, Xiao Jiang, Wei Li, Xueli Cai, Qiming Sun, Hu Hu   +11 more
wiley   +1 more source

Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]

, 2015
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte, Dane E. Karr, Danny Tam, David Finkle, David G. Loughhead, David M. Goldstein, Erik Verner, J. Hill, J. Michael Bradshaw, Jack Taunton, Jens Oliver Funk, Jesse M. Mcfarl, Jin Shu, Ken A. Brameld, Mary E, Philip A. Nunn, Principia Biopharma, Sergei Romanov, Timothy D. Owens, Tony Ton, Vaishali Patel, Vernon T. Phan, Ville O. Paavilainen, Xiaoyan Li   +23 more
core  

Profound Sinoatrial Arrest Associated with Ibrutinib

Case Reports in Oncological Medicine, 2017
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.
Kanupriya Mathur, Aditya Saini, Kenneth A. Ellenbogen, Richard K. Shepard   +3 more
doaj   +1 more source

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

Therapeutic Advances in Hematology, 2022
Bruton’s tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL).
Alexandra R. Lovell, Nadya Jammal, Prithviraj Bose   +2 more
doaj   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +3 more sources

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

Pharmacology Research & Perspectives, 2020
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders.
Krishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, Ankit Patel, Kinjal Thakkar, Dinesh Patel, Manoranjan Sharma, Jaideep Singh, Jogeswar Mohapatra, Abhijit Chatterjee, Dipam Patel, Rajesh Bahekar, Rajiv Sharma, Lakshmikant Gupta, Nirmal Patel, Poonam Giri, Nuggehally R. Srinivas, Mukul Jain, Debdutta Bandyopadhyay, Pankaj R. Patel, Ranjit C. Desai   +20 more
doaj   +1 more source